30: A Fully-Human Chimeric Antigen Receptor for Redirecting Specificity of T Cells to B-Lineage Tumors  by Manuri, P.R. et al.
Oral Presentations 13with CD41T cells from RORgt-/- vsWT donors suggest a signif-
icant survival benefit for recipients of RORgt-/- T cells. In conclu-
sion, these data suggest that CD41 Th17 cells contribute to the
development of acute GVHD.
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IL13 12044 (ARG130GLN) ASSOCIATES WITH ACUTE AND CHRONIC
GRAFT-VERSUS-HOST DISEASE FOLLOWING HAEMATOPOIETIC STEM
CELL TRANSPLANTATION
Leitch, E.A.1, Harrold, J.L.1, Ironside, A.1, Norden, J.1, Jackson, G.H.1,
Holler, E.2, Rocha, V.3, Socie, G.3, Hromadnikova, I.4, Sedlacek, P.4,
Greinix, H.5, Wolff, D.6, Urbano-Ispizua, A.7, Dickinson, A.M.1. 1 Uni-
versity of Newcastle, Newcastle upon Tyne, Tyne and Wear, United King-
dom; 2 University of Regensburg, Regensburg, Germany; 3 Hopital
Saint-Louis, Paris, France; 4 Charles University, Prague, Czech Republic;
5 University Hospital of Vienna, Vienna, Austria; 6 Universitat Rostock,
Rostock, Germany; 7 Hospital Clinic, Barcelona, Spain.
IL-13 is a T-helper 2 (Th2) cytokine that suppresses the cytotoxic
action of macrophages and inhibits the production of pro-inflam-
matory cytokines. A single nucleotide polymorphism (SNP) exists
within exon 4 of the IL13 gene at position 12044 which results in
an amino acid substitution (Arg130Gln). The high producer variant
(A allele) of this SNP, has been associated with several inflammatory
conditions, most notably asthma, and more recently IL-13 mixed
lymphocyte supernatant levels have been associated with aGvHD
in HSCT. Consequently the role of IL13 12044 SNP in HSCT
was examined in this investigation.
Polymorphism studies were carried out in a cohort of 923 HSCT
recipient and donors from 7 transplant centres across Europe. Gen-
otyping was performed using PCR and RFLP analysis. Univariant
(chi-squared) and multivariant (binary logistic regression) analyses
were performed to study associations and P values\0.05 were re-
garded as being statistically significant. Clinical factors such as re-
cipient age, gender mismatch (female donor/male recipient),
CMV status, stem cell source and treatment regimens were also in-
cluded in the analyses.
Multivariant analysis of the whole HSCT cohort demonstrated
that patients possessing the A allele were more susceptible to devel-
oping severe aGvHD (grades III-IV) (P5 0.028). Patients receiving
transplants from donors with the IL1312044 A allele were more at
risk of developing cGvHD (P 5 0.026). These associations re-
mained significant when the cohort was stratified for transplant
type (HLA-matched sibling andmatched unrelated donor) and con-
ditioning regimen (T replete vs deplete and reduced vs full intensity
conditioning). Significant associationswere also observed in a subset
of patients diagnosed with CML; HLA-matched sibling patients
possessing the IL13 12044 A allele were less likely to develop
cGvHD, whereas inMUD transplants donor possession of the A al-
lele was a risk for cGvHD. Depending on the subset analysis, clin-
ical factors, particularly peripheral blood stem cell transplants, were
significantly associated with GvHD.
To our knowledge this is the first investigation examining the role
of IL1312044 SNP in HSCT. The findings are extremely encour-
aging, indicating that IL1312044 SNP is associated with the devel-
opment of both aGvHD and cGvHD and consequently could
provide key pre-transplant information on GvHD prognosis.29
ADDITION OF ETANERCEPT TO METHYLPREDNISOLONE AS INITIAL
THERAPY FOR ACUTE GVHD RESULTS IN HIGH RESPONSE RATES AND
IMPROVED SURVIVAL
Levine, J.E., Paczesny, S., Mineishi, S., Braun, T., Choi, S.W.,
Hutchinson, R.J., Jones, D., Khaled, Y., Kitko, C.L., Bickley, D.,
Krijanovski, O., Reddy, P., Yanik, G., Ferrara, J.L.M. University of
Michigan, Ann Arbor, MI.
Standard therapy for GVHD, high dose steroids, results in com-
plete responses in only 35%of patients. Because tumor necrosis fac-
tor (TNF) is an important effector of GVHDwe treated 61 pts with
new onset GVHDwith methlyprednisolone 2 mg/kg/d plus etaner-
cept, a TNF inhibitor. All pts continued their prophylaxis agent,
usually tacrolimus, at therapeutic dosing.Etanercept was given subcutaneously 2 weekly for 8 wks at
a dose of 0.4 mg/kg/dose (max dose 25 mg). The outcomes in these
61 pts were compared to those of 99 contemporaneous pts with
GVHD whose initial therapy was steroids alone. Both groups of
pts were similar with respect to age, transplant conditioning inten-
sity, donor type, degree of HLA-match, and severity of GVHD at
onset. Pts who acheived CR by 4 wks did so without any second
line agents. Pts treated with etanercept plus steroids were signifi-
cantly more likely to achieve a complete response 4 wks later than
were pts treated with steroids alone [69% vs 33%, p\ 0.0001].
The benefit of etanercept persisted: at 12 wks after initiation of
GVHD treatment, 77% of etanercept plus steroids pts had achieved
CR compared to 50% of steroids alone pts (p5 0.0009). The supe-
riority of etanercept plus steroids over steroids alone was observed
in in all three target organs. Differences in steroid dosing did not
account for the difference in CR rate.
There was a trend for better survival at 6 mo following initiation
of GVHD treatment for the etanercept treated pts [p5 0.08] which
is explained by significantly superior survival in the unrelated donor
pts whoseGVHDwas treatedwith etanercept. Although related do-
nor pts who were treated with etanercept plus steroids were more
likely to be in CR at 4 wks [79% vs 39%, p 5 0.001], by 12 weeks
nearly equivalent proportions of pts in both groups achieved a CR
(etanercept plus steroids, 80%, steroids alone 70%) and 6 mo sur-
vival was similar. A greater proportion of unrelated donor pts
treated with etanercept were in CR at 4 wks [53% vs 26%, p 5
0.0005] but, unlike related donor pts, steroids alone pts who failed
to achieve a CR by 4 wks were likely to never achieve CR. This dif-
ference in overall CR rate translated into better survival six months
later [p 5 0.05].
Although not a randomized trial, these data strongly suggest that
etanercept plus steroids as initial therapy for acute GVHD results in
improved complete response rates compared to steroids alone and
may improve survival, especially for unrelated donor transplant pts.
Complete Response Rates at Four Weeks According to Treatment Group
Steroids Etanercept
alone plus steroids p valueOverall 33/99 (33%) 42/61 (69%) \0.0001
Skin 32/68 (47%) 30/37 (81%) 0.0008
Liver 3/15 (20%) 6/9 (67%) 0.03
GI 21/44 (48%) 29/37 (78%) 0.005
Presenting grade
Grade II 25/68 (37%) 31/40 (77%) 0.0001
Grade III/IV 8/31 (26%) 11/21 (52%) 0.0530
A FULLY-HUMAN CHIMERIC ANTIGEN RECEPTOR FOR REDIRECTING
SPECIFICITY OF T CELLS TO B-LINEAGE TUMORS
Manuri, P.R.1, Olivares, S.1, Dara, N.1, Dawson, M.J.1, Huls, H.1,
Lee, D.A.1, Shpall, E.J.2, Champlin, R.E.2, Cooper, L.J.N.1. 1 Children’s
Cancer Hospital, U.T.M.D. Anderson Cancer Center, Houston, TX;
2 U.T. MD Anderson Cancer Center, Hoouston, TX.
Adoptive therapy after allogeneic hematopoietic stem-cell trans-
plantation with ex vivo-expanded donor-derived tumor-specific T
cells to augment the graft-versus-leukemia (GVL) effect might be
used to reduce the incidence of leukemic relapse without exacerbat-
ing graft-versus-host disease. We previously showed that geneti-
cally modified peripheral- and umbilical cord blood-derived T
cells rendered specific for CD19, a molecule constitutively ex-
pressed on B-cell malignancies can augment GVL-effect. The re-
directed specificity was achieved by electro-transfer of a DNA
plasmid coding for the chimeric antigen receptor (CAR) that recog-
nizes CD19 via the scFv of a murine CD19-specific monoclonal an-
tibody (mAb) fused to T-cell activation endodomains. However,
14 Oral Presentationsa concern is that T cells bearing immunogenic transgenes, such as
those coding for mouse proteins, bacterial selection genes, or viral
suicide genes, would be targeted by the recipient’s immune system
and deleted. We report now that we have reduced the risk of clear-
ance of adoptively transferred genetically modified T cells due to
a host-versus-graft immune-mediated reaction directed to the xeno-
genic components of the CAR and its vector. To decrease immuno-
genicity, we generated a CD19-specific CAR encoded by all-human
transgenes (designated hCAR), wherein the murine CD19-specific
scFv is replaced with a human scFv of a CD19-specificmAb, derived
from mice immunized with CD19 and expressing human immuno-
globulin genes. Primary human T cells were electro-transferred
with the hCAR transgene, using Sleeping Beauty (SB) transposition,
and co-cultured with artificial antigen presenting cells expressing
CD19 antigen and co-stimulatorymolecules, resulting in expansion
and stable expression of hCAR without the need for concomitant
drug selection. The hCAR1 T cells could be detected by flow cy-
tometry and Western blot analysis and demonstrated specific lysis
of CD191 tumor targets. This report demonstrates technology
for generating CD19-specific hCAR1 T cells while avoiding ex-
pression of immunogenic proteins (e.g. murine scFv) and will likely
be of interest to the many investigators considering CAR1 T cells
for treatment of tumors.31
COMPREHENSIVE TYPING OF 1143 SINGLE NUCLEOTIDE POLYMOR-
PHISMS (SNP) IN 220 IMMUNOREGULATORY GENES DEMONSTRATES
THAT POLYMORPHISMS IN CCL3, CCL4 AND CCL27 MODULATE THE
RISK OF ACUTE GRAFT VERSUS HOST DISEASE (GVHD)
Mullally, A.1, Kim, H.2, Li, C.2, Mohseni, M.1, Ho, V.1, Alyea, E.P.1,
Antin, J.H.1, Soiffer, R.J.1, Ritz, J.1. 1 Dana Farber Cancer Institute,
Boston, MA; 2 Dana Farber Cancer Institute, Boston, MA.
A wide range of genetic polymorphisms has been studied in the
context of hematopoietic stem cell transplantation. To date, most
of these analyses have assessed a limited number of arbitrarily cho-
sen SNPs in a single or limited number of genes.We created an Af-
fymetrix custom SNP array and evaluated a total of 1143 SNPs in
220 distinct immune effector genes in 187 hematopoietic stem
cell transplant (HSCT) recipients and their sibling donors. Where
possible, SNPs that have been previously evaluated in the context
of GVHD (e.g. IL-10 SNPs) were included on the array. Genomic
DNA was extracted from peripheral blood mononuclear cells
(PBMC) obtained from patients and their sibling donors. All pa-
tients were in remission at the time of sampling, all had undergone
HSCT at theDana-Farber Cancer Institute between 1998 and 2005
and all samples were drawn prior to transplantation. The trans-
plants included myeloablative and non-myeloablative conditioning
regimens, T cell depleted (TCD) and non-TCD grafts and sex
matched and sex mis-matched donors. Using dChip software, we
evaluated each of the SNPs on the array in patients and in their do-
nors for an association between genotype and the development of
acute GVHD. Univariate and multivariate statistical analyses were
performed using the Cochran-Mantel-Haenzel test and a logistic
regression model adjusting for age, sex mismatch and other trans-
plant characteristics. The SNPs rs1063340 and rs1634508, that
are believed to regulate the function of CCL3 and CCL4 respec-
tively, were most highly associated with protection against aGVHD
(p\ 0.003), demonstrating an odds ratio (OR) of 0.6 for risk of
acute GVHD in the logistic regression analysis. The SNP
rs11575584, which is thought to regulate CCL27 was most highly
associated with risk of aGVHD (p 5 0.005), with an OR of 2 in
the same logistic regression model. CCL3 and CCL4 are chemo-
kine ligands for CCR5 while CCL27 is a skin-associated chemo-
kine, which interacts with the CCR10 receptor. The CCR5
deletion mutation (which protects against HIV infection) has re-
cently been associated with a reduced risk of aGVHD and increased
epidermal expression of CCL27 has been shown in patients with cu-
taneous aGVHD. This study is the most comprehensive evaluation
to date of functional genetic polymorphisms on the risk of aGVHD.
It suggests that the CCL3-CCL4-CCR5 andCCL27-CCR10 path-
ways play important roles in the pathogenesis of aGVHD and fur-
ther investigation of these pathways is warranted.32
ROLE OF STAT3 SIGNALING IN GVHD AND GVL
Radojcic, V., Pletneva, M.A., Yen, H.-R., Pardoll, D.M., Drake, C.G.,
Luznik, L. Johns Hopkins University.
Growing evidence suggests that STAT3 signaling in CD41 T-
cells plays a key role in the pathogenesis of autoimmunity. We
tested the role of the same pathway in the induction of GVHD
and GVL response in a murine model of alloSCT. Using the
MHC-matched B10.D2/BALB/c model in which GVHD is
CD41 T-cell-mediated and has clinicopathologic features consis-
tent with human chronic sclerodermatous GVHD, we examined
the role of STAT3 signaling in CD41 T-cells in the pathogenesis
of GVHD and GVL response. After conditioning (775 cGy) recip-
ient mice received B10.D2 T-cell depleted (TCD) bone marrow
(BM) and equivalent of 12  106 splenocytes (9.3  106 TCD sple-
nocytes, repleted with 106 wild-type (WT) CD81 and 1.8  106
WT, or CD4-Cre  STAT3flox/flox (STAT3KOCD41) T-cells),
a dose shown to induce all signs of GVHD. We reproducibly in-
duced all signs of chronic GVHD in chimeras receiving WT
CD41 T-cells, but not in chimeras injected with STAT3KOCD41
T-cells (median score of 0.0 vs. 5.2; P\ .001). In situ studies showed
that cutaneous GVHD was accompanied by prominent dermal in-
filtration of donor-derived inflammatory monocytes and complete
turnover to donor CD11c1 epidermal DC chimerism in chimeras
receivingWT but not STAT3KOCD41 T-cells (P\ .001). Splenic
CD11c1DCs, CD41 and CD81T-cell chimerismwas nearly com-
pletely donor-derived and did not differ between the two sets of de-
scribed chimeras. We also found that in this model, pathogenic
CD41T-cells do not acquireTH17 phenotype and that STAT3 sig-
naling disruption leads to expansion of Foxp31CD41 T-cells. To
examine the role of STAT3 pathway in eliciting GVL response,
we developed a model of preestablished disease in which 106 A20
lymphoma cells were administered to recipients 10 days prior to al-
loSCT. Addition of GVH inoculum containing STAT3KOCD41
T-cells enabled potent GVL response when compared to animals
receiving only TCD BM, or BM with added TCD SPL (P \
.001). However, it was inferior to that observed in the animals re-
ceiving WT CD41 T-cells (P\ .001). Our findings indicate that:
a) intact STAT3 signaling in CD41 T-cells is required for clinical
manifestations of GVHD in B10.D2/BALB/c model; b) commit-
ment of STAT3KOCD41 T-cells to regulatory Foxp31 lineage is
likely a result of their insensitivity to IL-6 in the abundance of
TGF-b; c) STAT3 ablation enables preservation of GVL, while re-
ducing clinicalmanifestations of GVHD. Further exploration of the
role of STAT3 pathway in posttransplant events is required.33
SIMILAR GRAFT-VERSUS-LEUKEMIA EFFECT USING MATCHED UNRE-
LATED DONORS, COMPARED TO HLA-IDENTICAL SIBLINGS FOR HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION
Ringden, O.T.H.1, Pavletic, S.2, Anasetti, C.3, Barrett, J.A.2,
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Arora, M.27. 1 Karolinska University Hospital Huddinge, Stockholm,
Sweden; 2 National Institutes of Health, Bethesda, MD; 3 H. Lee Moffitt
Cancer Center & Research Institute, Tampa, FL; 4 Medical College of
Wisconsin, Milwaukee, WI; 5 Brigham & Women’s Hospital, Boston,
MA; 6 Ospedale Civile, Pescara, Italy; 7 Cleveland Clinic Foundation,
Cleveland, OH; 8 Manitoba BMT Program, Winnipeg, MB, Canada;
9 Columbia University Medical Center, New York, NY; 10 Center for Ad-
vanced Studies in Leukemia, Los Angeles, CA; 11 MD Anderson Cancer
Center, Houston, TX; 12 Roswell Park Cancer Institute, Buffalo, NY;
13 St. Jude Children’s Research Hospital, Memphis, TN; 14 University
Hospital Basel, Basel, Switzerland; 15 Vanderbilt University Medical
Center, Nashville, TN; 16 Mayo Clinic, Rochester, MN; 17 IRCCS Policli-
nico San Matteo, Pavia, Italy; 18 USCF Children’ Hospital, San Fran-
cisco, CA; 19 Fred Hutchinson Cancer Research Center, Seattle, WA;
20 Tom Baker Cancer Center, Calgary, Canada; 21 UCLA School of
